secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001104659-24-071078
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune raises $100M in PIPE to fund RP1 commercialization; BLA filing on track for 2H 2024
--------------------------------------------------------------------------------

- Issued 5.67M shares at $8.82/share and 5.67M pre-funded warrants at $8.819/warrant.
- Gross proceeds ~$100M; expected closing June 14, 2024.
- Proceeds to fully scale up for RP1 commercial launch in skin cancers, potential path to profitability.
- Led by life-sciences institutional investor; Redmile, RTW, Boxer Capital participated.
- RP1 IGNYTE trial in anti-PD1 failed melanoma showed strong data; BLA submission expected 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465924071078/0001104659-24-071078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465924071078/tm2417173d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-071078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer